Current research suggests semaglutide may reduce some measures of alcohol craving and drinking in people with alcohol use disorder, but the evidence is still early and mixed. Semaglutide is not FDA-approved for alcohol use disorder, and the available trials are not yet enough to establish it as a standard AUD treatment.
What did the first randomized semaglutide trial find?
A 2025 randomized clinical trial studied once-weekly semaglutide in adults with alcohol use disorder. Compared with placebo, semaglutide reduced alcohol consumed during a laboratory self-administration task, reduced drinks per drinking day, and reduced weekly alcohol craving. It did not significantly reduce every drinking outcome.
What did the 2026 oral semaglutide trial find?
A 2026 phase 2 randomized trial of oral semaglutide found reductions in heavy drinking days, drinks per drinking day, and naturalistic alcohol craving compared with placebo. However, the study did not find a significant reduction in its primary laboratory cue-elicited craving outcome.
That difference is important: one type of craving measure improved while another did not.
Why might semaglutide affect alcohol craving?
GLP-1 receptor agonists influence appetite, satiety, and brain reward pathways. Researchers are investigating whether those effects also reduce the rewarding value or motivational pull of alcohol. The exact mechanisms in humans remain under study.
Does semaglutide reduce alcohol use in everyone?
No. Trial results are averages across small study groups, not guarantees for individuals. Response can vary, and the research has not yet established which patients are most likely to benefit.
Is semaglutide approved to treat alcohol use disorder?
No. Semaglutide is approved for certain diabetes and weight-management indications, not for AUD. Using it specifically for alcohol use disorder would be off-label.
How does this compare with established AUD medications?
Naltrexone, acamprosate, and disulfiram have established regulatory status for alcohol use disorder. Semaglutide is still being investigated and should not be presented as a replacement for approved AUD treatment based on current evidence.
Trinity has a broader guide on GLP-1 medications and alcohol use disorder research and another on medications used for AUD.
What research questions remain?
Larger studies need to clarify dose, duration, long-term drinking outcomes, safety, who benefits most, how semaglutide compares with approved AUD medications, and whether behavioral therapy changes outcomes.
Frequently asked questions
Has semaglutide been proven to treat alcohol cravings?
No. Early trials show promising signals, but the evidence remains preliminary.
Did every trial show craving reduction?
No. Different trials and different craving measures have produced mixed results.
Does Trinity prescribe semaglutide for AUD?
This article does not establish that Trinity offers or prescribes semaglutide for alcohol use disorder. Current treatment options should be verified directly.
Sources
- PubMed: Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
- PubMed: Oral Semaglutide for Alcohol Use Disorder
- NIH: GLP-1 Plus Therapy Can Reduce Heavy Drinking
This article summarizes emerging research and is not individualized medical advice.